KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ClearPoint Neuro (CLPT) EBIT Margin (2018 - 2025)

ClearPoint Neuro's EBIT Margin history spans 13 years, with the latest figure at 59.54% for Q3 2025.

  • For Q3 2025, EBIT Margin rose 414.0% year-over-year to 59.54%; the TTM value through Sep 2025 reached 66.31%, down 447.0%, while the annual FY2024 figure was 62.91%, 3080.0% up from the prior year.
  • EBIT Margin for Q3 2025 was 59.54% at ClearPoint Neuro, up from 61.64% in the prior quarter.
  • Across five years, EBIT Margin topped out at 54.12% in Q1 2021 and bottomed at 119.85% in Q2 2023.
  • The 5-year median for EBIT Margin is 73.75% (2022), against an average of 77.5%.
  • The largest annual shift saw EBIT Margin tumbled -4702bps in 2021 before it skyrocketed 5973bps in 2024.
  • A 5-year view of EBIT Margin shows it stood at 92.99% in 2021, then rose by 7bps to 86.37% in 2022, then increased by 20bps to 69.1% in 2023, then decreased by -5bps to 72.68% in 2024, then rose by 18bps to 59.54% in 2025.
  • Per Business Quant, the three most recent readings for CLPT's EBIT Margin are 59.54% (Q3 2025), 61.64% (Q2 2025), and 72.63% (Q1 2025).